Meeting
2021 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
Presenter
Mehdi Hamadani, MBBS
Division of Hematology and Oncology, Medical College of Wisconsin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04384484
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7574)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7574
Abstract #
TPS7574
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.
Speaker: Michal Kwiatek, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Speaker: Matthew J. Matasar, MD
Videos & Slides
2022 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
Speaker: Nancy L. Bartlett, MD
Videos & Slides
2022 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).
Speaker: Mehdi Hamadani, MBBS